QTTB: 82% | Q32 Bio shares are trading higher after the company it will report 36-week topline results from Part B of the SIGNAL-AA Phase 2a clinical trial on Monday, July 13, 2026.

 

AGEN: 36% | Agenus To Raise $85M To Fund Colon Cancer Drug Trial, Financing Could Reach $340M If Warrants Are Exercised

 

SHOP: 2% | Jefferies Upgrades Shopify to Buy, Raises Price Target to $160